Abstract
The design, synthesis, structure and the antimycobacterial activities of a new class of nitrogen heterocycles, namely N1-substituted-diphenyl ether-bis-pyridazine (BP), is presented. An efficient, facile and straight applicable method for preparation of BP derivatives is described. The primary cycle high throughput screening reveals that two BP compounds, 2a and 3b, are potent inhibitors against Mycobacterium tuberculosis (Mtb), with their antitubercular activity being superior to the second-line antitubercular drug Pyrimethamine and being equal to Cycloserine. The data from cycle-2 screening confirm the results from cycle-1. The MIC, MBC, LORA, intracellular (macrophage) drug screening, and MTT cell proliferation, indicate the intracellular drug effectiveness against Mtb of these compounds, the lack of toxicity, a significant activity against both replicating and non-replicating Mtb and, a bactericidal mechanism of action (for 2b). SAR correlations have been done. Overall, the BP derivatives and especially compound 2b, appeared as a new leading antitubercular structure, which makes it a promising lead for further drug development.
Keywords: Antimycobacterial, Bis-pyridazine, diphenyl ether linker, LORA, MBC, MIC, MTT, SAR.
Infectious Disorders - Drug Targets
Title:Design, Synthesis and Antimycobacterial Activity of Some New Pyridazine Derivatives: Bis-pyridazine. Part IV12-14
Volume: 13 Issue: 5
Author(s): Dorina Mantu, Vasilichia Antoci and Ionel I. Mangalagiu
Affiliation:
Keywords: Antimycobacterial, Bis-pyridazine, diphenyl ether linker, LORA, MBC, MIC, MTT, SAR.
Abstract: The design, synthesis, structure and the antimycobacterial activities of a new class of nitrogen heterocycles, namely N1-substituted-diphenyl ether-bis-pyridazine (BP), is presented. An efficient, facile and straight applicable method for preparation of BP derivatives is described. The primary cycle high throughput screening reveals that two BP compounds, 2a and 3b, are potent inhibitors against Mycobacterium tuberculosis (Mtb), with their antitubercular activity being superior to the second-line antitubercular drug Pyrimethamine and being equal to Cycloserine. The data from cycle-2 screening confirm the results from cycle-1. The MIC, MBC, LORA, intracellular (macrophage) drug screening, and MTT cell proliferation, indicate the intracellular drug effectiveness against Mtb of these compounds, the lack of toxicity, a significant activity against both replicating and non-replicating Mtb and, a bactericidal mechanism of action (for 2b). SAR correlations have been done. Overall, the BP derivatives and especially compound 2b, appeared as a new leading antitubercular structure, which makes it a promising lead for further drug development.
Export Options
About this article
Cite this article as:
Mantu Dorina, Antoci Vasilichia and Mangalagiu I. Ionel, Design, Synthesis and Antimycobacterial Activity of Some New Pyridazine Derivatives: Bis-pyridazine. Part IV12-14, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526514666140217144707
DOI https://dx.doi.org/10.2174/1871526514666140217144707 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Dermatology and Global Health Meet Pharmacogenomics: Cutaneous Leishmaniasis
Current Pharmacogenomics and Personalized Medicine Thermal Stability of Thermoanaerobacter tengcongensis Ribosome Recycling Factor
Protein & Peptide Letters Evolution of the DUT Gene: Horizontal Transfer between Host and Pathogen in all Three Domains of Life
Current Protein & Peptide Science Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Clinical Development of Microbicides for the Prevention of HIV Infection
Current Pharmaceutical Design DNA Vaccines.
Current Molecular Medicine Regulation of Cell Wall Synthesis and Growth
Current Molecular Medicine Editorial [ Hot Topic: Potential Targets for the Rational Design of Antiparasitic Drugs (Executive Editor: Mahmoud H. el Kouni) ]
Current Pharmaceutical Design Editorial (Thematic Issue: Recent Trends in Library Design and Virtual Screening in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry Abiotic Regulation: A Common Way for Proteins to Modulate their Functions
Current Protein & Peptide Science Microwave-assisted Single Step Cinnamic Acid Derivatization and Evaluation for Cytotoxic Potential
Current Pharmaceutical Biotechnology Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Phytochemistry, Antinociceptive and Anti-inflammatory Actvities of Methanolic Leaves Extract of Lannea schimperi (Hoschst. Ex Rich) ENG.
Recent Patents on Biotechnology Targeting Bacterial RNA Polymerase σ70 for Development of Broadspectrum Antisense Antibacterials
Recent Patents on Anti-Infective Drug Discovery Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Subject Index To Volume 8
Current Pharmaceutical Design Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design